Orexo Valuation Multiples

Orexo Overview

About Orexo

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo’s groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo’s headquarters in Uppsala, Sweden.

Founded

1995

HQ

Employees

110

Website

orexo.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3M

EBITDA: ($30M)

EV

$54M

Valuation Multiples

Multiples.vc

Start free trial

Orexo Financials

Orexo reported last 12-month revenue of $3M and negative EBITDA of ($30M).

In the same LTM period, Orexo generated $1M in gross profit, ($30M) in EBITDA losses, and $50M in net income.

Orexo P&L

In the most recent fiscal year, Orexo reported revenue of $3M and EBITDA of ($30M).

Orexo expects next 12-month revenue of XXX and NTM EBITDA of XXX

Orexo Stock Performance

Orexo has current market cap of $99M, and enterprise value of $54M.

Orexo's stock price is $2.86.

Orexo Valuation Multiples

Orexo trades at 19.7x EV/Revenue multiple, and (1.8x) EV/EBITDA.

Orexo Financial Valuation Multiples

As of March 21, 2026, Orexo has market cap of $99M and EV of $54M.

Equity research analysts estimate Orexo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Orexo has a P/E ratio of 2.0x.

Orexo Margins & Growth Rates

Orexo's revenue in the last 12 month declined by (2%).

Orexo's revenue per employee in the last FY averaged $0.0M.

Orexo's rule of 40 is (1082%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Orexo's rule of X is (1086%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Orexo Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Orexo M&A Activity

Orexo acquired XXX companies to date.

Last acquisition by Orexo was on XXXXXXXX, XXXXX. Orexo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Orexo Investment Activity

Orexo invested in XXX companies to date.

Orexo made its latest investment on XXXXXXXX, XXXXX. Orexo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).